For biotech companies, the IPO is like a debutante ball—a grand public coming-out party where you hope to dazzle

Venture capital and private equity thrive on numbers—IRRs, TVPIs, MOICs—each acronym an attempt to quantify success in an

There are many books about how to make money. There are far fewer about how people actually lose it. What

There are very few finance books that you can read without needing a double espresso or a minor existential crisis

The integration of artificial intelligence (AI) into drug discovery is reshaping pharmaceutical development, prompting regulatory bodies to adapt their frameworks

Venture capital, like any industry where past success is difficult to verify, has a long tradition of being economical with

Every year, the pharma industry rolls out its latest batch of “game-changing,” “best-in-class,” and “first-in-class” therapies, showering them with press

capable of wreaking havoc if overindulged. For biotech founders staring down the barrel of cash burn and trial delays, it

Focusing on the real-world impacts of neglecting Extreme Value Theory (EVT), particularly in biotechnology and pharmaceuticals, offers a potent narrative.

The biotech world thrives on optimism. Pitch decks brimming with breakthroughs and life-saving treatments are a staple of the industry’